Number 5: Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory ...

Biosimilar SB12 demonstrated comparable efficacy and safety for paroxysmal nocturnal hemoglobinuria (PNH) to its reference drug, showing similar outcomes across diverse patient groups.

Explore the latest advancements in rheumatology biosimilars, including FDA approvals, patient switching trends, and ...

Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, explain that widespread biosimilar adoption requires addressing patient and provider education gaps through pharmacists and ...

Number 5: Explore how real-world evidence and biosimilars enhance insulin access and adherence, improving diabetes care and outcomes for patients who have type 2 diabetes. Number 4: The new data were ...

Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory bowel ...

The debate over the Biosimilar Red Tape Elimination Act raises critical concerns about FDA standards, physician trust, and ...

"Escaping the Void: All Things Biosimilars With Craig & G" with cohosts Craig Burton, executive director of the Biosimilars Council, and Giuseppe (G) Randazzo, senior vice president of sciences and ...

Juliana Reed, executive director of the Biosimilar Forum, stated when she took over the role, “I am extremely excited to lead the most influential organization for the biosimilars industry at such a ...